ArticleInternational journal of nanomedicine2025
Article in International journal of nanomedicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: In this study, Methods: We prepared GP-PF NPs through heating. A comprehensive structural characterization of the GP-PF NPs was conducted through particle size, zeta potential, electron microscopy, and spectroscopy studies, and their self-assembly mechanism was preliminarily elucidated through molecular dynamics and molecular docking. Subsequently, the analgesic effects of the GP-PF NPs and free PF were evaluated using an acetic acid writhing model, and the in vivo processes were analyzed using pharmacokinetic studies. Finally, the mechanism of transmembrane transport of GP-PF NPs was investigated in Caco-2 cells. Results: The GP-PF NPs showed a consistent spherical shape with a 150 nm diameter and a zeta potential of -84 mV, providing excellent stability. The molecular dynamics and docking results indicated that GP-PF NPs have stable molecular dynamic characteristics. In the writhing mouse models, GP-PF NPs reduced the number of writhing events compared with the PF group, indicating stronger analgesic effect. The pharmacokinetic analysis showed that the GP-PF NPs exhibited a significant 2.60-fold increase in the maximum plasma concentration of PF and a significant 0.95-fold increase in the area under the curve of PF compared with free PF ( Conclusion: GP-PF NPs enhanced PF's oral bioavailability and analgesic performance by increasing intestinal absorption through caveolin-dependent endocytosis. Thus, GP may be a potential carrier for increasing the oral bioavailability of PF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.